BioAegis Therapeutics Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 13

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $20M

  • Investors
  • 3

BioAegis Therapeutics General Information

Description

Operator of a clinical-stage drug development platform intended to facilitate the treatment of inflammation and infectious diseases. The company's platform specializes in the research and development of drugs to restore plasma gelsolin - innate immunity that provides an immunotherapeutic approach to fighting pathogens, enabling hospitals to begin treatment and result in a high likelihood of successful treatment.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Corporate Office
  • Commercialization Center for Innovative Technology
  • 675 US Highway One
  • North Brunswick, NJ 08902
  • United States
+1 (973) 000-0000

BioAegis Therapeutics Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BioAegis Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Grant 16-Oct-2023 $20M 000.00 Completed Clinical Trials - Phase 2
9. Later Stage VC 22-Mar-2022 0000 000.00 Completed Clinical Trials - Phase 2
8. Later Stage VC (Series C) 31-Dec-2021 0000 000.00 Completed Clinical Trials - Phase 2
7. Later Stage VC 07-Oct-2020 000 000.00 Completed Clinical Trials - Phase 2
6. Debt - PPP 28-Apr-2020 000.00 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series B) 01-Aug-2018 00.00 000.00 000.00 Completed Clinical Trials - General
4. Grant 09-Jul-2016 000 000.00 Completed Clinical Trials - General
3. Later Stage VC 11-Mar-2016 00.00 000.00 0000 Completed Startup
2. Early Stage VC (Series A) 01-Jan-2015 $8.04M $11M 0000 Completed Startup
1. Angel (individual) 08-Feb-2013 $3M $3M Completed Startup
To view BioAegis Therapeutics’s complete valuation and funding history, request access »

BioAegis Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage drug development platform intended to facilitate the treatment of inflammation and infectio
Drug Discovery
North Brunswick, NJ
13 As of 2024
000.00
0000000000 000.00

00000

t labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitat
0000 000000000
Watertown, MA
00 As of 0000
00000
000000000 00000

000000

rcitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute iru
0000 000000000
London, United Kingdom
00 As of 0000
00000
00000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BioAegis Therapeutics Competitors (13)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vigil Neuro Formerly VC-backed Watertown, MA 00 00000 000000000 00000
AviadoBio Venture Capital-Backed London, United Kingdom 00 00000 00000000000 00000
Asceneuron Venture Capital-Backed Lausanne, Switzerland 00 00000 00000000000 00000
Inhibikase Therapeutics Corporation Atlanta, GA 0 000.00 000000000 000.00
Inflammasome Therapeutics Venture Capital-Backed Newton, MA 00.00 000000000 00.00
You’re viewing 5 of 13 competitors. Get the full list »

BioAegis Therapeutics Patents

BioAegis Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021347408-A1 Compositions and methods for identifying and treating microparticle-associated diseases and conditions Pending 23-Sep-2020 00000000000
CA-3196026-A1 Compositions and methods for identifying and treating microparticle-associated diseases and conditions Pending 23-Sep-2020 00000000000
EP-4204818-A1 Compositions and methods for identifying and treating microparticle-associated diseases and conditions Pending 23-Sep-2020 00000000000
AU-2021347408-A9 Compositions and methods for identifying and treating microparticle-associated diseases and conditions Pending 23-Sep-2020 00000000000
US-20230398176-A1 Compositions and methods for identifying and treating microparticle-associated diseases and conditions Pending 23-Sep-2020 A61K38/16
To view BioAegis Therapeutics’s complete patent history, request access »

BioAegis Therapeutics Executive Team (15)

Name Title Board Seat
Susan Levinson Ph.D Co-Founder, Board Member & Chief Executive Officer
Valerie Ceva Co-Founder, Board Member & Chief Operating Officer
Steven Cordovano Co-Founder & Vice President of Corporate Development and Communications
John Kellum MD Clinical Advisory Board Member
Taylor Thompson MD Clinical Advisory Board Member
You’re viewing 5 of 15 executive team members. Get the full list »

BioAegis Therapeutics Board Members (7)

Name Representing Role Since
Kerry Maguire Self Board Member 000 0000
Kris Vinckier BioAegis Therapeutics Board Member 000 0000
Mark DiNubile MD BioAegis Therapeutics Chief Medical Officer & Board Member 000 0000
Susan Levinson Ph.D BioAegis Therapeutics Co-Founder, Board Member & Chief Executive Officer 000 0000
Valerie Ceva BioAegis Therapeutics Co-Founder, Board Member & Chief Operating Officer 000 0000
You’re viewing 5 of 7 board members. Get the full list »

BioAegis Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioAegis Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Biomedical Advanced Research and Development Authority Government 000 0000 000000 0
European Investment Fund Fund of Funds Minority 000 0000 000000 0
National Institute Of Allergy and Infectious Diseases Government 000 0000 000000 0
To view BioAegis Therapeutics’s complete investors history, request access »

BioAegis Therapeutics FAQs

  • When was BioAegis Therapeutics founded?

    BioAegis Therapeutics was founded in 2011.

  • Who is the founder of BioAegis Therapeutics?

    Susan Levinson Ph.D, Valerie Ceva, Steven Cordovano, and Thomas Stossel MD are the founders of BioAegis Therapeutics.

  • Who is the CEO of BioAegis Therapeutics?

    Susan Levinson Ph.D is the CEO of BioAegis Therapeutics.

  • Where is BioAegis Therapeutics headquartered?

    BioAegis Therapeutics is headquartered in North Brunswick, NJ.

  • What is the size of BioAegis Therapeutics?

    BioAegis Therapeutics has 13 total employees.

  • What industry is BioAegis Therapeutics in?

    BioAegis Therapeutics’s primary industry is Drug Discovery.

  • Is BioAegis Therapeutics a private or public company?

    BioAegis Therapeutics is a Private company.

  • What is BioAegis Therapeutics’s current revenue?

    The current revenue for BioAegis Therapeutics is 000000.

  • How much funding has BioAegis Therapeutics raised over time?

    BioAegis Therapeutics has raised $56.7M.

  • Who are BioAegis Therapeutics’s investors?

    Biomedical Advanced Research and Development Authority, European Investment Fund, and National Institute Of Allergy and Infectious Diseases have invested in BioAegis Therapeutics.

  • Who are BioAegis Therapeutics’s competitors?

    Vigil Neuro, AviadoBio, Asceneuron, Inhibikase Therapeutics, and Inflammasome Therapeutics are some of the 13 competitors of BioAegis Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »